Tumor Immunology and Immunotherapy
- Publisher's listprice GBP 237.50
-
113 465 Ft (108 062 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 11 347 Ft off)
- Discounted price 102 119 Ft (97 256 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
113 465 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher OUP Oxford
- Date of Publication 29 May 2014
- ISBN 9780199676866
- Binding Hardback
- No. of pages470 pages
- Size 253x176x27 mm
- Weight 1076 g
- Language English 0
Categories
Short description:
Tumor immunology and immunotherapy provides a comprehensive account of cancer immunity and immunotherapy. Examining recent results, current areas of interest and the specific issues that are affecting the research and development of vaccines, this book provides insight into how these problems may be overcome as viewed by leaders in the field.
MoreLong description:
Patients are beginning to benefit from antibody based, cellular and vaccine approaches that are effective against genetically diverse and therapy-resistance cancers. BCG immunotherapy is now being used as a first line treatment for human bladder cancer and the introduction of prophylactic vaccination against Hepatitis B and HPV cancers is starting to show positive results. Following recent FDA approval for a vaccination against prostate cancer, and optimistic results in clinical trials for a vaccine targeting cancer antigens in lung cancer, cancer immunotherapy is now significantly impacting patient clinical management.
Tumor Immunology and Immunotherapy provides an up-to-date and comprehensive account of cancer immunity and immunotherapy. It discusses our adaptive and innate immunity to cancer, the mechanisms underpinning our immune response, current approaches to cancer immunotherapy, and how tumour and host responses can circumvent effective anti-cancer immunity.
The book examines recent results, publications and current areas of interest including 'immune editing' and the specific issues that are affecting the research and development of vaccines, providing insight into how these problems may be overcome, as viewed by world leaders in the field. Tumor Immunology and Immunotherapy will appeal to clinicians working in oncology and cancer immunotherapy, and research scientists including PhD and masters students, post-doctoral researchers and senior investigators.
Overall, this book provides a good overview of cancer immunotherapy with specific insights into the main clinical treatments and experimental approaches for specialists.
Table of Contents:
Adaptive T-cell immunity and tumor antigen recognition
Impact of aging and body mass on cancer immunotherapy outcomes
The potential of natural killer cells in cancer immunotherapy
The tumour microenvironment: the role of tumour associated macrophages in cancer progression and responses to therapy
"Hard" and "soft" loss of MHC class I expression in cancer cells
Modulation of the adaptive immune system through chronic inflammation and T-regulatory responses
Myeloid-derived suppressor cells: immune suppressive cells that facilitate tumor progression and promote and deter cancer-associated inflammation.
Triggering death receptors as a means of inducing tumoricidal activity
Identification of tumor antigens for clinical evaluation
Viral antigens as targets for prophylactic and therapeutic intervention in cancer
HER-2/neu as a target for vaccine and antibody directed therapies
Pre-clinical evaluation of immunotherapy: the case for prostate cancer and the tramp model
Tumor-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapy
Predictive biomarkers to better select patients for cancer immunotherapy
Viral platforms for expression of tumour antigens in cancer immunotherapy
Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignancies
DNA vaccines
Programming the immune system through childhood infections: MUC1 Tumor Associated Antigen (TAA) as a Disease Associated Antigen (DAA)
Vaccination against myeloid leukaemias using newly defined antigens
Immune-checkpoint blockade in cancer immunotherapy
Multi-peptide cancer vaccines for clinical application
Adoptive T-cell therapy using TILs for the treatment of metastatic melanoma
Chimeric antigen receptor gene therapy in cancer
The vaccinal effect of monoclonal antibodies in cancer therapy
Antibody therapies: defining appropriate cell surface epitopes for targeting tumours
Adoptive lymphocyte (stem cell) therapy in cancer
Cancer Stem Cells (CSCs) and Epithelial-to-Mesenchymal Transition (EMT): Tumor Cell Plasticity Challenges Immunotherapy
Immune escape and aging of the immune system compromises the immune response to tumor antigens
